Kidney Cancer

Kidney cancer is generally more common in men than in women over the age of 64, being very rare in people under 45. It is among the 10 most common cancers in both men and women.

LifEscozul™ - Kidney Cancer

LifEscozul™ - Kidney Cancer

The incidence has increased since the 1990s, probably due to the use of new imaging studies, such as CT scans, which can find some cancers that otherwise would never have been detected. Mortality rates for these cancers have declined slightly since the mid-1990s. Five-year survival rates for kidney cancer range from 81 to 8% depending on the stage of the cancer.

Treatment options offered by conventional medicine range from surgery, tumor ablation, radiation therapy, active surveillance, chemotherapy, targeted therapy on cancer-specific genes and proteins, immunotherapy. The treatment options and effectiveness for patients with advanced cancer are mostly aimed at keeping the disease under control for as long as possible and relieving symptoms.

Escozul™ can be administered in conjunction with any conventional treatment. Escozul™ is intended to work not only on the cancer but also on the patient's quality of life. Its analgesic and anti-inflammatory effects help to improve the quality of life in about 65 to 75% of the patients treated. Through its antitumor effect, depending on the stage, one of the following results is expected: to be able to slow down the progression of the disease, to stop tumor growth, to reduce the size of lesions or to eliminate tumor lesions.

It is important to point out that Escozul™ is not considered a cure for cancer, it is a natural medicine that converts this deadly disease into a controlled chronic one, offering also quality of life.

Results in different cases

Renal cancer with lung metastases, mass in renal bed/left adrenal gland, pulmonary thrombi in left renal vein and inferior vena cava. Patient: Enrique Age: 77

Patient with advanced renal cancer with multiple metastases manages to eliminate tumor lesions in lungs and decrease the size of the lesion in the renal bed/left adrenal gland after 11 months of treatment…

Enrique is a 77-year-old patient who was diagnosed with renal cancer in 2014 and operated on. He presented with recurrence of the disease in 2016 with involvement in lungs, renal bed/left adrenal gland, and tumor thrombi. He came to us through his daughter, seeking treatment alternatives for his disease.

Case summary:

We share today the case of a 77-year-old patient who came to us in June 2016, with a diagnosis of stage IV renal cancer who had undergone surgery in 2014 and presented with recurrence in 2016 with multiple tumor lesions.

When we received the medical documentation we were able to ascertain that Enrique had been diagnosed with renal cancer and operated on, but subsequently the disease recurred presenting retroperitoneal tumor mass in surgical bed position and left adrenal gland, with extension to tumor thrombi in left renal vein and inferior vena cava, in addition to presenting pulmonary mass.

As for symptoms, she presented low back pain, difficulty with eating and sleeping, worry, depression, disorientation, weight loss, constant and uncontrollable diarrhea for long periods of time.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results. In such an advanced case, it was expected to help slow down or even stop the progression of the disease.

Each dose of Escozul™ is personalized, specific to the type and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Enrique started treatment with Escozul™ in June 2016.

Evolution, Follow-up and Current Results:

We received Enrique's first follow-up report in August 2016, shortly after starting Escozul™, in which a decrease in the size of the retroperitoneal lesion (in renal bed/adrenal gland position) was beginning to be observed, the main lesion in lung had disappeared, although some adenopathies persisted.

In a new CT scan in January 2017, the lesion in the renal/adrenal bed decreased again and no tumors were observed in the lungs; the metastases at this level disappeared completely.

In May 2017, almost a year after starting Escozul™, he remains without lung lesions, and the lesion in renal bed/left adrenal gland, has decreased to a size of 27.5×13.3mm, being its size at the beginning of the treatment 65x51mm, which represents a total decrease of more than 80% of the size of the recurrent lesion.

These results have contributed to Enrique having a better quality of life and a longer survival expectancy.

Enrique continues the treatment with Escozul™ in progressively increasing doses, always seeking to improve the results obtained so far and to avoid a new progression of the disease.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

As we always say, it is important to note that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group August/2017

Medical Documents

LifEscozul™ - Enrique 1 - Cáncer de Riñon
LifEscozul™ - Enrique 2 - Cáncer de Riñon
LifEscozul™ - Enrique 3 - Cáncer de Riñon
LifEscozul™ - Enrique 4 - Cáncer de Riñon
LifEscozul™ - Enrique 5 - Cáncer de Riñon
LifEscozul™ - Enrique 6 - Cáncer de Riñon
LifEscozul™ - Enrique 7 - Cáncer de Riñon
LifEscozul™ - Enrique 8 - Cáncer de Riñon
LifEscozul™ - Enrique 9 - Cáncer de Riñon
LifEscozul™ - Enrique 10 - Cáncer de Riñon
LifEscozul™ - Enrique 11 - Cáncer de Riñon

Kidney Cancer Patient: Aldo Age: 59 years old

We share today the case of Aldo, a patient with stage IV kidney cancer, 59 years old, in treatment with Escozul™ since August 2015 who contacted us looking for an alternative to the progression of his disease.

Case summary:

Upon sending us the requested information we were able to ascertain that this was a case of left renal cancer (Fuhrman grade II clear cell carcinoma) that had been operated on in June 2014, but multiple metastases had appeared in both lungs.

Aldo presented a change in his appetite, as well as decreased energy.

We also had the opportunity to talk with his oncologist, who was interested in the characteristics of the Escozul™ treatment and the possibility of using it in conjunction with oral chemotherapy.

He began treatment with Escozul™ in August 2015 with the initial decision to treat him with a high dose and high concentration-progressive because according to the extent of the disease and what had been observed in similar cases, it was advisable. Periodic check-ups were also proposed.

It is important to say that Escozul™ is a natural product which has been shown to have the capacity to eliminate tumor cells, without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the focus of the work is done so that the patient can live with his disease with the least possible impact on his daily routine.

Evolution, follow-up and current results:

A follow-up was established mostly in terms of imaging tests (CT), since in the case of renal cancer no tumor markers are performed. Blood tests were also requested periodically.

Three weeks after starting treatment, Aldo reported that he felt more appetite and energy and gained 4 kilos in weight. These early symptoms are consistent with what has been observed in other patients with good response to Escozul™ treatment.

By October 2015, two months after starting treatment, a CT scan study showed an increase in size and number of pulmonary lesions, so the dosage of Escozul™ was increased in order to control the evolution of the disease. It is necessary to consider that two months is not enough time to observe a response in terms of tumor control. In spite of this, the patient told us that he had gained 4 more kilos and that he remained in good physical condition and in good spirits.

Finally in the last CT scan of January 2016, the lesions began to decrease in size and number, considering that the disease was beginning to be controlled. We then proceeded to a new dose increase, seeking to continue such reduction.

Currently Aldo continues with Escozul™ treatment, with progressive dose increases, always seeking to control and reduce the disease. He has kept in contact with us periodically, allowing our specialists to closely monitor the case and take the necessary measures to obtain the best possible results.

In such an advanced case, being able to improve Aldo's quality of life and achieve a reduction in the size and number of his lesions in a period of 6 months is undoubtedly a positive result. Aldo has gained weight and does not present symptoms that make us think that he is sick and although there is still a long way to go, his evolution gives us hope.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, nor does Escozul™ work miracles. Only working together and constant communication allows us to keep the doses of Escozul™ personalized and functional against tumors.

It is important to say that all the information of the case is available for consultation as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

You can find more information about Escozul™ on our website: www.escozul-cuba.com or if you would like to receive advice from our specialists please write to us at: servicios@lifescozulcuba.com

Medical Documents

LifEscozul™ - Aldo 1 - Cáncer de Riñon
LifEscozul™ - Aldo 2 - Cáncer de Riñon
LifEscozul™ - Aldo 3 - Cáncer de Riñon
LifEscozul™ - Aldo 4 - Cáncer de Riñon
LifEscozul™ - Aldo 5 - Cáncer de Riñon
LifEscozul™ - Aldo 6 - Cáncer de Riñon
LifEscozul™ - Aldo 7 - Cáncer de Riñon
LifEscozul™ - Aldo 8 - Cáncer de Riñon
LifEscozul™ - Aldo 9 - Cáncer de Riñon
LifEscozul™ - Aldo 10 - Cáncer de Riñon
LifEscozul™ - Aldo 11 - Cáncer de Riñon
LifEscozul™ - Aldo 12 - Cáncer de Riñon

Kidney Cancer Patient: Maria Age: 79 Country: Chile

Patient with kidney cancer, operated on, and with metastasis to the lungs who cannot receive chemo, remains asymptomatic after 2 and a half years of treatment with Escozul™.

Case summary:

Patient with kidney cancer, operated, and metastasis to lungs who is unable to receive chemo, remains asymptomatic after 2.5 years of treatment with Escozul™.

Initial Diagnosis:

Started on Escozul™ in September 2012. Patient was not a candidate for chemotherapy due to poor remaining kidney function, in addition to being diabetic and hypertensive.

  •  - Mild back pain
  • - Listlessness
  • - Perspiration
  • - Tiredness

Treatment with Escozul™:

Right kidney cancer operated on in November 2011 (renal cell carcinoma, clear cell variety), with metastasis to lungs in March 2012 finding tumor mass in left lung and multiple nodules in both lungs.

Escozul™ is a natural product that has the ability to eliminate tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine.

Evolution of the case:

After the first treatment, despite the persistence of symptoms, the patient reported feeling better and more cheerful.

At three months the pain had disappeared and the patient was in good spirits. At six months the patient's physical condition was considered excellent with mild back discomfort.

At the 6, 9 month follow-up after the start of treatment the patient remained in good physical condition and stable. At 12 months after the start of treatment, the patient did not show any symptoms that demonstrated the presence of disease. She has remained in good physical condition and symptom-free at every three-monthly check-up. Blood tests revealed no alarming data beyond the alterations of a diabetic patient and with only one kidney functioning at 50%.

Current results:

In April 2015, after 2 years and 7 months on treatment with Escozul™ alone, the patient is in good physical condition, with no symptoms evidencing that she is suffering from any disease. Unfortunately, in this case there are no imaging tests that allow us to see the stage of the disease at pulmonary level, since the patient, due to her renal disease, should not undergo tests with administration of contrast medium. In spite of this, it can be concluded that the disease is stable or has diminished, since the patient does not present any symptoms of disease or any deterioration at the respiratory level, which accompanies the progression of the cancer at the lung level, such as shortness of breath, weight loss, respiratory difficulty, cough.

The patient continues to consume Escozul™ with progressive doses in search of maintaining these results.

Summary:

It has been achieved in this case, to improve the patient's quality of life and control the disease, preventing her health from deteriorating, which is very important considering also that this patient has no other treatment options by conventional medicine.

The patient is leading a normal life with her family, without the disease affecting her activities and physical and mental well-being.

Medical Documents

LifEscozul™ - María 1 - Cáncer de Riñon
LifEscozul™ - María 2 - Cáncer de Riñon
LifEscozul™ - María 3 - Cáncer de Riñon
LifEscozul™ - María 4 - Cáncer de Riñon
LifEscozul™ - María 5 - Cáncer de Riñon
LifEscozul™ - María 6 - Cáncer de Riñon

Renal Cancer Patient: Mateo Age: 78 years old

Patient with metastatic renal cancer with lymph node and pulmonary metastases, in partial regression after 9 months of treatment with Escozul™.

Case summary:

Patient with metastatic operated renal cancer with lymph node, and lung metastases, in partial regression after 9 months of treatment with Escozul™.

Initial Diagnosis:

Right kidney cancer (operated clear cell and papillary carcinoma) with retroperitoneal lymph node metastases and secondary pulmonary nodules.

Initial symptoms:

- Back pain

- Difficulty with rest

- Loss of appetite

- Irritability

Escozul™ treatments:

Started on Escozul™ in August 2014. Patient had received surgery to remove right kidney, finding adrenal gland involvement, tumor invasion of lymphatic and blood vessels. The patient did not undergo chemotherapy or radiotherapy.

Escozul™ is a natural product that has the ability to eliminate tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine.

Current results:

In comparative Tac of thorax, abdomen and pelvis, after 9 months in uninterrupted treatment with Escozul™, reduction of retroperitoneal adenopathies is observed (from 3.7cm the largest to 2.5cm), regression of nodular lesions in pulmonary parenchyma. There is no appearance of new lesions or extension of the disease. Improvement in quality of life has also been achieved, reducing symptoms to fatigue.

Summary:

The patient continues to consume Escozul™ with progressive doses in search of maintaining these results.

The patient is leading a normal life with his family, without the disease affecting his activities and physical and mental well-being.

Medical Documents

LifEscozul™ - Mateo 1 - Cáncer de Riñon
LifEscozul™ - Mateo 2 - Cáncer de Riñon
LifEscozul™ - Mateo 3 - Cáncer de Riñon
LifEscozul™ - Mateo 4 - Cáncer de Riñon
LifEscozul™ - Mateo 5 - Cáncer de Riñon